Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant neutrophil inhibitory factor and hirulog hybrid
- Development stage
- Unknown
- Lead developer
- Shandong New Time Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant neutrophil inhibitory factor and hirulog hybrid, also called **TNHH**, is an investigational recombinant hybrid glycoprotein developed for acute ischemic stroke. It combines a neutrophil inhibitory factor-derived component that binds the neutrophil integrin CD11b/CD18 with a hirulog-derived direct thrombin-inhibitory component, aiming to simultaneously limit neutrophil adhesion and migration and reduce thrombin-mediated coagulation at ischemic thrombi. A first-in-human randomized, placebo-controlled, single-ascending-dose study in healthy volunteers evaluated intravenous TNHH at 0.05-1.8 mg/kg; it showed high CD11b/CD18 occupancy at doses above 0.2 mg/kg and dose-related prolongation of thrombin time. The program has been associated with West China Hospital, Chongqing Fagen Biomedical, and Shandong New Time Pharmaceutical.
- Other names
- TNHHtargeted neutrophil inhibitory-hirulog hybridhuman recombinant neutrophil inhibitory factor and hirulog hybrid
02
Targets
F2 (Thrombin)αMβ2 (Integrin αMβ2)
Beyond the preview
Go deeper on recombinant neutrophil inhibitory factor and hirulog hybrid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant neutrophil inhibitory factor and hirulog hybrid.